Interaction between cd14 and hbv components
OwnerGeert Leroux-Roels, Peter Van Landschootinventors
Life of this patent
Estimating the term…
Abstract
The present invention is based on the finding that HBV components (HBsAg) binds to CD14. LPS binding protein catalyses the attachment of HBsAg to CD14. The invention more particularly describes molecules having HBV receptor activity. The invention further describes molecules and compounds for preventing, treating or alleviating inflammatory reactions in patients. The invention also relates to new compounds directed against HBV infections, and methods for identifying them, including in vitro and in vivo model systems to do so. The invention further relates to new vaccine compositions directed against HBV. Additionally the invention also relates to the use of HBV components to treat inflammatory diseases.
Claims24
Method for determining the binding between CD14 and Hepatitis B virus components comprising the use of:
- a) CD14, or a mutein, or a fragment of CD14 which is able to bind to HBV antigens or particles,
- b) HBV components,
- c) a ligand or antisense peptide of the molecules mentioned in a) or b),
- d) an antibody raised against any of the molecules mentioned in a) or b),
- e) an antibody raised against the ligand mentioned in c),
- f) an anti-idiotype antibody raised against the antibody mentioned in d), or
- g) an anti-idiotype antibody raised against the antibody mentioned in e).
Composition for preventing, treating or alleviating HBV infections comprising as an active substance at least one of the following:
- a) CD14 or a mutein or fragment thereof which binds to HBV components,
- b) a ligand or antisense peptide of the molecules mentioned in a),
- c) an antibody raised against the molecules mentioned in a),
- d) an antibody raised against the ligand or antisense peptide mentioned in b),
- e) an anti-idiotype antibody raised against the antibody mentioned in c), or
- f) an anti-idiotype antibody raised against the antibody mentioned in d),
A composition for preventing, treating or alleviating HBV infections comprising as an active substance an antibody against a ligand of HBV components, wherein said ligand is the LPS binding protein.
A composition for preventing, treating or alleviating HBV infections comprising as an active substance a peptide which blocks the binding of the LPS binding protein to HBV components.
Use of HBV components for preventing, treating or alleviating inflammatory reactions.
Use of HBV components for the preparation of a medicament for preventing, treating or alleviating inflammatory reactions.
A host cell transformed with a nucleic acid sequence coding for a fragment of CD14 which binds to HBV components, said fragment comprising the sequence as represented in SEQ ID NO 1, and with said host expressing said fragment on its surface.
Compound obtained by any of the methods of claims 11 to 13 or 24.
Use of HBV components in combination with LPS binding protein for preventing, treating or alleviating inflammatory reactions.
Use of HBV components in combination with LPS binding protein for the preparation of a medicament for preventing, treating or alleviating inflammatory reactions.
Dependencies are inferred from the claim text.